Class summary at a glance.

Every drug in the Nucleoside Metabolic Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 16tracked in Part D
CY24 Part D spend: $215.2Mcombined across class
Total Rx claims: 1.1M944K unique beneficiaries
Generic mfrs (active): 97across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Azacitidine

Brand: ONUREG · 8K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2004-07-05

13 generic mfrs 654 plans require PA Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend $138.5M

Class share

64%

of class CY24 spend

View profile →

Fluorouracil

Brand: Efudex · 1.0M Part D claims (CY24) · 921K beneficiaries · First FDA approval: 1970-07-29

10 generic mfrs 2 plans require PA

Low NADAC$0.600

→

Avg plan cost$1.73

Part D spend $68.4M 3× spread, current vs floor

Class share

32%

of class CY24 spend

View profile →

Mercaptopurine

64K Part D claims (CY24) · 19K beneficiaries · First FDA approval: 2004-02-13

3 generic mfrs 68 plans require PA

Low NADAC$1.04

→

Avg plan cost$1.04

Part D spend $6.8M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Gemcitabine

Brand: AVGEMSI · 5K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2010-11-15

13 generic mfrs Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $782622

Class share

of class CY24 spend

View profile →

Decitabine

493 Part D claims (CY24) · 112 beneficiaries · First FDA approval: 2013-07-11

16 generic mfrs Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $530406

Class share

of class CY24 spend

View profile →

Pentostatin

Brand: Nipent · 17 Part D claims (CY24) · First FDA approval: 2007-08-15

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $91645

Class share

of class CY24 spend

View profile →

Capecitabine

Brand: XELODA · 249 Part D claims (CY24) · 80 beneficiaries · First FDA approval: 1998-04-30

11 generic mfrs

Low NADAC$0.396

→

Avg plan cost$0.458

Part D spend $74309 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cytarabine

41 Part D claims (CY24) · 13 beneficiaries · First FDA approval: 1990-06-04

7 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $557

Class share

of class CY24 spend

View profile →

(Daunorubicin and Cytarabine) Liposome

Brand: VYXEOS · — Part D claims (CY24) · First FDA approval: 2017-08-03

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Azacitidine For

Brand: AZACITIDINE · — Part D claims (CY24) · First FDA approval: 2024-03-14

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Cedazuridine and Decitabine

Brand: INQOVI · — Part D claims (CY24) · First FDA approval: 2020-07-07

Brand-only (no generics) 327 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Clofarabine

— Part D claims (CY24) · First FDA approval: 2017-05-10

8 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Fludarabine

Brand: Fludarabine · — Part D claims (CY24) · First FDA approval: 2007-11-16

5 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Fluorouracil Cream,

Brand: FLUOROURACIL · — Part D claims (CY24) · First FDA approval: 2025-07-06

Brand-only (no generics) 6 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Gemcitabine Intravesical

Brand: INLEXZO · — Part D claims (CY24) · First FDA approval: 2025-09-14

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Nelarabine

Brand: Arranon · — Part D claims (CY24) · First FDA approval: 2016-10-05

10 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.